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Abstract
Inositol phospholipids and inositol phosphates mediate well-
established functions in signal transduction and in Ca2+
homeostasis in the CNS and non-neural tissues. More
recently, there has been renewed interest in other roles that
both myo-inositol and its highly phosphorylated forms may
play in neural function. We review evidence that myo-inositol
serves as a clinically relevant osmolyte in the CNS, and that
its hexakisphosphate and pyrophosphorylated derivatives
may play roles in such diverse cellular functions as DNA
repair, nuclear RNA export and synaptic membrane traf-
ficking.
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The prominent role of inositol phospholipids in signal
transduction events within the CNS is now well established
(for reviews, see Fisher and Agranoff 1987; Fisher et al.
1992). In addition, roles for phosphoinositides as facilitators
of a diverse array of cellular events, such as membrane
trafficking, maintenance of the actin cytoskeleton, regulation
of cell death and survival, and anchors for plasma membrane
proteins, have been documented (for reviews, see Toker and
Cantley 1997; Low 2000; Vanhaesebroeck et al. 2001). In
contrast, with the notable exception of inositol 1,4,5-
trisphosphate and its pivotal role in the mobilization of
intracellular calcium, less emphasis has been placed on the
functional significance of the water-soluble components of
the phosphoinositide pathway, i.e. myo-inositol and its
phosphorylated derivatives. To date, seven of the 63 possible
inositol phosphate esters have been assigned putative phy-
siological roles (Irvine and Schell 2001), and many others
have been detected in a variety of organisms. In addition, at
least four pyrophosphorylated inositol phosphates and
enzymes that synthesize (Huang et al. 1998; Saiardi et al.
2001b) and degrade them (Safrany et al. 1998; Caffrey et al.
2000) in brain have been identified. Given their structural
diversity, it appears likely that cellular functions of other
inositol phosphates remain to be discovered.
In this review, we focus on the role that myo-inositol
itself and some of its highly phosphorylated derivatives
(namely, inositol hexakisphosphate and the diphosphoino-
sitol polyphosphates) may play in neural function. The CNS
is an atypical tissue in that it possesses relatively high
concentrations of myo-inositol as well as the means to
synthesize it. myo-Inositol serves not only as a precursor
molecule for inositol lipid synthesis, but also as a physi-
ologically important osmolyte. Alterations in brain and CSF
inositol concentrations have been reported in a number of
pathological conditions. In addition, oral administration of
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inositol has been claimed to be of therapeutic benefit in the
treatment of several neuropsychiatric disorders. Inositol
hexakisphosphate (IP6; phytate) is the most abundant of the
inositol phosphates in both neural and non-neural cells. In
common with myo-inositol, IP6 is particularly prevalent in
the CNS. IP6 binding sites have been identified (Sasakawa
et al. 1995), and a number of functions highly relevant to
the CNS have been proposed. IP6 was held to be the most
highly phosphorylated inositol-containing molecule until the
discovery of pyrophosphate-containing derivatives, which
has added yet another level of complexity to our under-
standing of both the metabolism and the function of inositol
phosphates. The diphosphoinositol polyphosphates are
readily synthesized by enzymes derived from the CNS
and exhibit a rapid turnover, and are thus likely to play
significant roles in neural function.
Inositol
Historical overview
A crystalline product derived from muscle extracts and
having the empirical formula of a carbohydrate was discov-
ered some 150 years ago (Scherer 1850) and was termed
‘inosit’, from inos the Greek root for muscle, and which was
translated into English as ‘inositol’. It was later predicted to
be one of nine possible stereoisomers of hexahydroxycyclo-
hexane (Bouveault 1894), of which seven were correctly
predicted to be optically inactive and of the remaining two to
be an enantiomeric pair (Fig. 1). The inositol isomer
described by Scherer was found to be naturally abundant,
and was eventually identified as its hexakisphosphate ester,
phytic acid, a common component of many foods, especially



























































































Fig. 1 Structures and nomenclature of the inositols. Of the nine
possible isomers of hexahydroxycylcohexane, myo-inositol is by far
the most prevalent in nature. The term ‘cyclitol’ can be used to refer
to the nine inositols collectively. When the term inositol is used
without a prefix, it is inferred to be the myo isomer. Viewed in its
favored chair configuration (a), myo-inositol has one axial and five
equatorial hydroxyl groups. A convenient mnemonic device for
visualizing the molecule three dimensionally is to consider it as a
turtle (IUPAC-IUB Commission on Biochemical Nomenclature (CBN)
1992) in which the D1 position is the right front limb and the head
(axial) is position D2. Looking down from above and continuing
counter-clockwise, the left front limb becomes D3, etc. A pyro-
phosphoryl inositol polyphosphate is shown to illustrate the useful-
ness of the ‘turtle’ in visualizing this molecule. It should be
cautioned that inositol phosphates, like inositol, are not rigid mole-
cules, and actual conformations are expected to reflect the regional
ionic environment within the cellular milieu. (b) Names and struc-
tures of the other eight cyclitols. About a tenth of brain cyclitol is
scyllo-inositol, and neo-inositol has been detected in trace amounts
in brain.
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nature from the eight other isomeric inositols, it was renamed
myo-inositol. When one uses the term inositol without a
prefix, it is generally presumed that one is referring to the
myo isomer, whereas the term ‘inositols’ refers to all nine.
Inositol was one of a number of ‘bios’ growth factors
established to be required by some microorganisms (Eastcott
1928). A nutritional deficiency in laboratory animals could
not be easily demonstrated, presumably because of the
ubiquitous presence of inositol in the diet, and the ability of
some tissues to convert D-glucose-6-phosphate to D-inositol-
3-phosphate, which could then be dephosphorylated to
inositol. In addition, dietary phytate can in some instances
give rise to free inositol, either by the action of ingested
dietary phytases or from endogenous phytase activity in the
intestinal mucosa. Cultured human cell lines that are
dependent on inositol have been identified, some of which
can synthesize inositol, but presumably not in sufficient
quantities to support maximal growth (Eagle et al. 1960).
Although the human diet typically provides 1 g/day of
inositol (Holub 1986), approximately 4 g/day could be
synthesized by the kidneys (Clements and Diethelm 1979;
see Fig. 2). Brain and testis also synthesize inositol (Hauser
and Finelli 1963), but the kidney is by far the major organ
involved in its catabolism and excretion. Inositol degradation
occurs via a specific oxygenase that cleaves the polyol ring
with the resulting production of D-glucuronic acid (Chara-
lampous 1958; Arner et al. 2001). The latter is then
metabolized in the liver to D-xylulose 5-phosphate and
enters the pentose phosphate pathway (see Fig. 2).
A special function for inositol in the nervous system was
first suggested by the discovery of a relatively high inositol
content in the brains of many species (Young 1934; Long
1961). Folch found that cephalin contained lipid-bound
inositol (Folch and Woolley 1942), which was eventually
shown to be one of three phosphoinositides: phosphatidyl-
inositol (PI), phosphatidylinositol-4-phosphate (PI4P) and
phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]. Evidence
that the inositol lipids are metabolically highly active
was first noted in manometric studies (Sloane-Stanley
1953), and later by means of 32P labeling (Eichberg and
Dawson 1965). Eventually, the high rate of turnover
could be explained by evidence that they were components
of the phosphoinositide-mediated signal transduction system
(Berridge 1987).
Most of the other eight isomers of myo-inositol, largely the
result of chemical or microbial action on myo-inositol
hexaphosphate produced by plant grains, have been isolated
as phosphate esters from soil. A number of derivatized
cyclitols, mainly methyl ethers, are also present in plants
(Posternak 1965). Scyllo-inositol is present in human brain in
quantities estimated to be from 5 to 12% that of myo-inositol
(Seaquist and Gruetter 1998). Rat and rabbit brains contain
an epimerase that converts myo- to scyllo-inositol via a
myo-scyllo-inosose intermediate (Sherman et al. 1968a,b),
PI4P
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Fig. 2 Sources and metabolic fates of inositol in humans. The inositol
intake in the human diet is estimated to be about 1 g per day, arising
from free inositol, or derived by hydrolysis of ingested phytate or to a
lesser extent, of inositol lipids. Some tissues, including brain endo-
thelium, have the ability to form inositol from glucose 6-P. CSF is
enriched seven-fold in inositol relative to blood (plasma), whereas the
brain inositol concentration is some 200-fold higher. Inositol levels in
neuronal and glial cells derived from various species can be between
three and four times that of whole brain. Inositol degradation is
exclusively via conversion to glucuronic acid in the kidney, followed by
further degradation in the liver. Free inositol is required for synthesis of
phosphatidylinositol (PI). Its formation from higher inositol phosphates
is blocked by Li+ (see text). The formation of IP5-IP8 is depicted in
Fig. 3.
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but it is not known whether brain scyllo-inositol is synthe-
sized in situ or how much of it is transported into the brain
via the blood (Spector 1978). Levels of both myo and scyllo
isomers can be measured non-invasively in the human brain
by means of 1H-spectral shift NMR. Neo-inositol has been
reported to be present in mammalian brain, but at much
lower concentrations (Sherman et al. 1971). Small quantities
of labeled chiro-inositol are reported in the rat brain
following intraperitoneal injection of 3H-labeled myo-inositol
(Pak et al. 1992). At present, phosphates of inositols other
than myo-inositol have not been reported in brain or other
animal tissues. However, it has been recently learned that
Entamoeba histolytica contains neo-inositol phosphates
(Martin et al. 2000).
Distribution of inositol in CNS and other neural tissues
Inositol in tissues and other biological samples can be
isolated from other polyols by TLC and, following derivati-
zation, separated by GLC, and then identified by retention
times and quantified by means of a variety of detectors (cited
in Kouzuma et al. 2001). It can also be selectively measured
in a mixture by means of specific bacterial dehydrogenases
(Kouzuma et al. 2001). With the exceptions of the testis,
kidney and lens of the eye, the mammalian CNS contains
significantly higher concentrations of inositol than non-
neural tissues. As is the case in non-neural cells (Sigal et al.
1993), it is likely that inositol in neural tissues is not in a
single compartment (Wolfson et al. 2000). If the assumptions
are made, for purposes of comparison, that each wet weight
gram or mL of brain contains 100 mg of protein, and that its
dry weight comprises 20% of wet wight, then intracellular
concentrations of inositol present in whole brain, gross
anatomical regions or peripheral nerves can be calculated to
range from 2 to 15 mM. These concentrations of inositol
exceed those present in the CSF and plasma by 25–50- and
50–100-fold, respectively (see Table 1). Within the CNS,
relatively similar concentrations of inositol are reported for
distinct regions of either human (Shimon et al. 1998) or rat
brain (Patishi et al. 1996). However, at least in human brain,
the absolute values may not remain constant throughout life
because concentrations of inositol in temporal cortex decline
by > 50% between the ages of 20 and 90 (Stokes et al. 1983).
Inositol is also readily lost from brain tissue when cell
integrity is compromised. Thus when slices are prepared
from cerebral cortex, hippocampus or cerebellum, there is a
50–60% loss of inositol (Table 1).
It remains uncertain to what extent inositol is preferentially
concentrated within neuronal or glial cells. It has been
suggested that inositol is primarily (Glanville et al. 1989), or
even exclusively (Brand et al. 1993), localized to the glia.
However, inositol concentrations in some neuronal popula-
tions may equal or exceed those observed for glia. Concen-
trations of inositol approaching 10–20 mM have been
reported for the Purkinje cell layer of the cat cerebellar
flocculus (Godfrey et al. 1982), and for the giant neurons of
Deiter’s nucleus in the rabbit (Sherman et al. 1977). These
values are similar to those obtained for cultured human
NT2-N neurons or SH-SY5Y neuroblastoma cells (Novak
et al. 1999). In other neuronal types, inositol concentrations
are distinctly lower. For example, the concentration of
inositol in cultured rat cerebellar granule cells is < 25% of
that in NT2-N neurons (Novak et al. 1999), and HCN-2
human neurons are reported to be less than 1 mM in inositol
(Koch et al. 1999).
Molecular mechanisms for maintenance of inositol
concentrations
In addition to the recycling of inositol phosphate second
messengers, cells maintain their intracellular concentration of
inositol via three distinct mechanisms: transport of inositol
across the plasma membrane via specific carrier molecules,
de novo synthesis of D-inositol 3-phosphate from D-glucose
6-phosphate, and the efflux of inositol, which is mediated via
a volume-sensitive organic osmolyte channel.
Na+/myo-inositol transporter
Concentrations of inositol in neural cells typically exceed
those in plasma by a wide range, from 2- to 500-fold (Sigal
et al. 1993). This concentration of the polyol is accom-
plished primarily by a saturable Na+-dependent uptake
mechanism that exhibits a high affinity for inositol and is
mediated by a specific sodium myo-inositol transporter
(SMIT) molecule, originally cloned from canine MDCK
cells (Kwon et al. 1992). From its cDNA, a protein of 718
amino acids with 12 membrane-spanning domains is
predicted (molecular weight; MW ¼ 79.5 kDa). Both the
amino and carboxyl termini of SMIT are cytoplasmic, and
several potential phosphorylation sites for either protein
kinase A or protein kinase C are found in the cytoplasmic
domains. Canine SMIT exhibits 40–50% homology with the
Na+/D-glucose cotransporters of rabbit intestinal mucosa and
kidney proximal tubules (Hediger et al. 1987; Coady et al.
1990). Human SMIT is highly homologous to the canine
transporter (Berry et al. 1995). The gene encoding human
SMIT (SLC5A3) appears to be a complex transcriptional
unit that consists of at least five exons subject to alternate
splicing (Porcellati et al. 1998), and is overexpressed in
Down’s syndrome (see below).
The transport characteristics of cloned renal SMIT were
examined in detail following expression in Xenopus oocytes
(Hager et al. 1995). Uptake is pH-dependent and requires
two Na+ ions for each molecule of inositol transported.
Half-maximal uptake occurs at 50 lM, and phlorizin is a
potent competitive inhibitor. Myo- and scyllo-inositols are the
preferred substrates for transport, with the rank order
efficacy for transport for a number of carbohydrates
being myo-inositol ¼ scyllo-inositol > L-fucose > L-xylose
> L-glucose, D-glucose, 3-O-methyl-D-glucose, 2-deoxy-
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Table 1 Concentrations of myo-inositol in neural tissues
Inositol concentrations
Cell/tissue Reported Calculated (mM)a Reference
Human brain
frontal cortex 5.8 mmol/kg wet wt 5.8 Shimon et al. (1998)
occipital cortex 5.8 mmol/kg wet wt 5.8 Shimon et al. (1998)
cerebellum 5.1 mmol/kg wet wt 5.1 Shimon et al. (1998)
temporal cortex (age 20) 60 lmol/g protein 6.0 Stokes et al. (1983)
temporal cortex (age 90) 27 lmol/g protein 2.7 Stokes et al. (1983)
temporal cortex 4.4 lmol/g wet wt 4.4 Stokes and Hawthorne (1987)
Human
CSF 22 ng/lL 0.12 Shetty et al. (1995a)
plasma 2.8 ng/lL 0.02 Shetty et al. (1995b)
sural nerve 26 000 pmol/mg protein 2.6 Sundkvist et al. (2000)
NT2-N neurons 195 nmol/mg protein 17.4c Novak et al. (1999)
HCN-2 neurons < 1 mM < 1 Koch et al. (1999)
SK-N-SH neuroblastoma 60 nmol/mg protein 6.0 Stubbs and Agranoff (1993)
SH-SY5Y neuroblastoma 112 nmol/mg protein 11.2 Novak et al. (1999)
1321 N1 astrocytoma 80 nmol/mg protein 8.0 Novak et al. (1999)
Rat brain
whole brain 11.5 mmol/kg wet wt 11.5 Lohr et al. (1988)
whole brain 6.6 lmol/g wet wt 6.6 Palmano et al. (1977)
whole brain 5.8 mmol/kg wet wt 5.8 MacGregor and Matschinsky (1984)
cerebral cortex 2.1 mmol/kg wet wt 2.1 Patishi et al. (1996)
cerebral cortex 21 mmol/kg dry wt 4.2 Sherman et al. (1986)
cerebral cortex 2.3 mmol/kg wet wt 2.3 Belmaker et al. (1998)
cerebral cortex (gray) 61 nmol/mg protein 6.1 Novak et al. (1999)
cerebral cortex (white) 80 nmol/mg protein 8.0 Novak et al. (1999)
cerebral cortex (slices) 21 nmol/mg protein 2.1 Stubbs and Agranoff (1993)
cerebral cortex (slices, washed) 9 nmol/mg protein 0.9 Stubbs and Agranoff (1993)
hypothalamus 3.7 mmol/kg wet wt 3.7 Patishi et al. (1996)
hypothalamus 33 mmol/kg dry wt 6.6 Sherman et al. (1986)
hypothalamus 4.4 mmol/kg wet wt 4.4 Belmaker et al. (1998)
cerebellum 3.4 mmol/kg wet wt 3.4 Patishi et al. (1996)
cerebellum 31 mmol/kg dry wt 6.2 Sherman et al. (1986)
cerebellum 3.1 mmol/kg wet wt 3.1 Belmaker et al. (1998)
cerebellum (slices) 38.3 nmol/mg protein 3.8 Heacock et al. (1993)
cerebellum (slices, washed) 17.0 nmol/mg protein 1.7 Heacock et al. (1993)
cerebellum: molecular layer 29 mmol/kg dry wt 5.8 MacGregor and Matschinsky (1984)
cerebellum: granular layer 23 mmol/kg dry wt 4.6 MacGregor and Matschinsky (1984)
cerebellum: granular layer 22 mmol/kg dry wt 4.4 Sherman et al. (1977)
cerebellum: medullary layer 27 mmol/kg dry wt 5.4 MacGregor and Matschinsky (1984)
hippocampus 3.6 mmol/kg wet wt 3.6 Patishi et al. (1996)
hippocampus 34 mmol/kg dry wt 6.8 Sherman et al. (1986)
hippocampus 3.1 mmol/kg wet wt 3.1 Belmaker et al. (1998)
hippocampus (slices) 30.3 nmol/mg protein 3.0 Heacock et al. (1993)
hippocampus (slices, washed) 11.5 nmol/mg protein 1.15 Heacock et al. (1993)
caudate 2.8 mmol/kg wet wt 2.8 Patishi et al. (1996)
caudate 19 mmol/kg dry wt 3.8 Sherman et al. (1986)
caudate 2.7 mmol/kg wet wt 2.7 Belmaker et al. (1998)
Rat
serum 0.1 lmol/mL 0.1 Palmano et al. (1977)
serum 63.7 lM 0.06 MacGregor and Matschinsky (1984)
sciatic nerve 3.1 lmol/g wet wt 3.1 Palmano et al. (1977)
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D-glucose > D-xylose. In contrast, the specificity for trans-
port by the Na+/glucose cotransporter (SGLT1) is D-glucose,
a-methyl-D-glucopyranoside, D-galactose, D-fucose, 3-O-
methyl-D-glucose > D-xylose, L-xylose, 2-deoxy-D-glucose
>myo-inositol, L-glucose, L-fucose. Uridine is transported
by an Na+/nucleoside transporter, which exhibits consider-
able homology to both SGLT1 and SMIT (61% and 47%,
respectively), although neither SMIT nor SGLT1 is able to
transport uridine.
SMIT, as determined by expression of its mRNA, is
widely distributed throughout the CNS and is found in both
neural and non-neural cells. There are striking regional
differences in the expression of SMIT mRNA, with highest
levels observed in the choroid plexus, pineal, hippocampus,
locus cœruleus and Purkinje cells. Although the distribution
of mRNA for SMIT is distinctly uneven, all brain regions
possess the transcript for the transporter (Inoue et al. 1996).
In contrast, only relatively small differences in Vmax (0.2–
0.5 nmol/mg protein/min) have been reported for SMIT
measured in astrocyte preparations derived from major brain
regions, including cerebral cortex, hippocampus, cerebellum,
diencephalon and tegmentum (Isaacks et al. 1997, 1999c;
Lubrich et al. 2000). Km values for the high affinity transport
of inositol in these distinct regions are also relatively similar
(13–50 lM; see Table 2). In terms of development, expres-
sion of both the mRNA and SMIT protein is highest in fetal
brain and declines postnatally (Guo et al. 1997). This pattern
of expression may be linked to the high concentration of
inositol in fetal CSF (Battaglia et al. 1961). As observed for
the adult brain, mRNA for SMIT is diffusely distributed
throughout the fetal brain and spinal cord with positive
signals observed for both neural and non-neural cells. The
developmental pattern for SMIT in kidney is completely
opposite of that observed for brain: renal SMIT mRNA
expression is low during embryogenesis and increases
significantly after birth (Guo et al. 1997).
Both the expression and activity of SMIT can be regulated
by a number of factors, the best documented of which is
osmotic stress. This has been demonstrated both in vivo
(Ibsen and Strange 1996) and in vitro for cultured glia
(Strange et al. 1991, 1994; Isaacks et al. 1997), neuroblas-
toma (Wiese et al. 1996) and human NT2-N neurons (Novak
et al. 1999). In response to hyperosmolar stress
(> 330 mOsm), the expression of SMIT mRNA increases
several-fold, as does the activity of the transporter. SMIT
gene expression can be regulated by five tonicity-responsive
enhancers scattered throughout the 5¢-flanking region of the
gene (Rim et al. 1998). The increase in rat SMIT mRNA
occurs only after several hours and precedes increased
activity of the transporter (Ibsen and Strange 1996). The
latter, which is associated with an increase in the Vmax of
SMIT without a change in Km, is blocked in the presence of
Table 1 (Continued)
Inositol concentrations
Cell/tissue Reported Calculated (mM)a Reference
sciatic nerve 2.7 mmol/kg wet wt 2.7 MacGregor and Matschinsky (1984)
cerebellar granule cells 41 nmol/mg protein 4.1 Novak et al. (1999)
astroctyes: cerebral cortex 120 nmol/mg protein 12.0 Strange et al. (1994)
astrocytes: cerebral cortex 25.6 lg/mg protein 14.2 Isaacks et al. (1994)
astrocytes: cerebral cortex 26.6 lg/mg protein 14.9 Isaacks et al. (1999a)
C6 glioma 28 nmol/mg protein 31.0
c Strange et al. (1991)
Rabbit
giant neurons of Deiter’s nucleus 44 mmol/kg dry wt 8.8 Sherman et al. (1977)
dorsal root ganglion 21 mmol/kg dry wt 4.2 Sherman et al. (1977)
spinal cord, anterior horn 56 mmol/kg dry wt 11.2 Sherman et al. (1977)
Cat
molecular layer of cerebellar flocculusb 17.4 mmol/L 17.4 Godfrey et al. (1982)
auditory nerve 10 mmol/L 10.0 Godfrey et al. (1982)
facial nerve 14.5 mmol/L 14.5 Godfrey et al. (1982)
vestibular nerve 12 mmol/L 12.5 Godfrey et al. (1982)
Mouse
whole brain 4.8 mmol/kg wet wt 4.8 Thurston et al. (1989)
Guinea pig
cerebral cortex 48 mmol/kg dry wt 9.6 Sherman et al. (1986)
aInositol intracellular concentrations are calculated on the basis that each g wet wt of tissue contains 100 mg of protein. Dry weight is assumed to
comprise 20% of wet weight (Long 1961). bSee reference for additional brain regions. cCalculated on the basis of measured intracellular volumes.
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cycloheximide, thereby indicating a requirement for de novo
protein synthesis. Conversely, when cells are returned to
iso-osmotic conditions, SMIT mRNA levels decrease rapidly
and inositol is slowly lost by passive efflux. Whereas SMIT
transcripts are broadly distributed throughout the brain, there
are marked regional differences in the magnitude of
increased expression of SMIT mRNA in response to
hypertonicity (Ibsen and Strange 1996; Bitoun and Tappaz
2000). Following increases in plasma osmolarity, significant
increases in SMIT mRNA levels were observed for the rat
cerebral cortex, habenula and nucleus accumbens, but little
increase occurred in the caudate-putamen. Similarly, plasma
hypertonicity increases SMIT mRNA in the inferior, but not
in the superior, colliculi (Ibsen and Strange 1996). Increases
in mRNA for SMIT were also observed following the
intraperitoneal administration of kainic acid, a treatment that
results in an intensive neuronal discharge and a concomitant
increase in the concentration of intracellular electrolytes. The
increases in SMIT mRNA were most pronounced in the
frontal and parietal cortex (Nonaka et al. 1999).
SMIT expression is also regulated by inositol. Thus, when
cultured astrocytes obtained from the cerebellum, cerebral
cortex, hippocampus or tegmentum were pre-treated with
400 lM inositol for 1–15 days there was a time-dependent
reduction of SMIT activity, which reached its maximum
(approximately 30%) at day 8 (Lubrich et al. 2000). In
contrast, SMIT activity in astrocytes obtained from the
diencephalon is not down-regulated by inositol. The latter
observation, along with the differential regulation of SMIT
activity by corticosterone and hyperosmolarity (Lubrich
et al. 2000), may suggest the presence of distinct SMIT
isoforms in different brain regions. SMIT may also be
regulated by anti-bipolar therapeutic drugs such as Li+,
valproate or carbamazepine, each of which is reported to
reduce the activity of the transporter (Lubrich et al. 2000).
The activity of SMIT may also be regulated by protein
kinase C, the activation of which results in an inhibition of
the transporter in human astrocytoma cells (Batty et al. 1993)
and human NT2-N neurons (Novak et al. 2000). In contrast,
activation of protein kinase A does not alter the activity of
SMIT in NT2-N neurons (Novak et al. 2000).
H+/myo-inositol symporter
A novel mammalian inositol transporter has recently been
identified from the screening of databases for sequences
related to SGLT. However, this molecule does not transport
glucose or other hexoses, but is an H+-myo-inositol sym-
porter (HMIT; Uldry et al. 2001). HMIT cDNA encodes a
618 amino acid polypeptide with 12 predicted transmem-
brane domains (MW approximately 75–90 kDa, depending
upon the extent of glycosylation). HMIT is expressed almost
exclusively within the CNS, primarily within astrocytes, but
it is also present in some neuronal populations. Of interest
are the pH-dependencies of the two transporter types. Thus
whereas SMIT is progressively inhibited by a reduction in





NT2-N neurons 36 0.06 Novak et al. (1999)
1321 N1 astrocytoma 40 0.18 Batty et al. (1993)
Rat
Astrocytes
Cerebral cortex 13–18 0.16 Isaacks et al. (1997)
26 0.19 Isaacks et al. (1999c)
50 0.47 Lubrich et al. (2000)
Cerebellum 27 0.20 Lubrich et al. (2000)
Hippocampus 50 0.30 Lubrich et al. (2000)
Diencephalon 27 0.19 Lubrich et al. (2000)
Tegmentum 48 0.21 Lubrich et al. (2000)
C6 glioma 15 0.12 Paredes et al. (1992)
B50 neuroblastoma 14 0.02 Reboulleau (1990)
Fetal brain cells 35 0.01 Fruen and Lester (1991)
Rabbit
Peripheral nerve 83 0.01 Greene and Lattimer (1982)
Mouse
Astrocytes (cerebral cortex) 25 0.06 Wiesinger (1991)
NB41A3 neuroblastoma 46 0.15 Wiese et al. (1996)
Neuroblastoma 12 0.01 Yorek et al. (1986)
Table 2 Kinetic characteristics of Na+/myo-
inositol transporter in neural tissues
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low pH. Although the physiological significance of HMIT
has yet to be established, this transporter might mediate an
additional regulatory mechanism of inositol homeostasis.
Inositol synthesis
Inositol is synthesized de novo from glucose in a number of
organs, including brain, testis, kidney and liver (Hauser and
Finelli 1963). The trimeric enzyme D-inositol-3-phosphate
synthase catalyzes the irreversible cyclic aldol condensation
of glucose-6-phosphate to yield D-inositol-3-phosphate
(L-inositol-1-phosphate; Eisenberg 1967; Culbertson et al.
1976; Maeda and Eisenberg 1980). The reaction requires
nicotinamide adenine dinucleotide (oxidized) (NAD), is
stimulated by NH4
+ and K+, and is inhibited by Li+. The
D-inositol-3-phosphate produced is then hydrolyzed by the
Mg2+-dependent Li+-inhibitable enzyme inositol monophos-
phatase (IMPase). No synthase activity could be detected in
human NT2-N neurons (Novak et al. 1999). This result is
consistent with previous immunocytochemical data localiz-
ing the brain enzyme primarily to the capillary endothelium
(Wong et al. 1987).
Inositol efflux
In response to hypotonic stress, inositol efflux occurs from
both neurons and glia via a facilitated diffusion mechanism
that involves a non-specific Cl– channel. Based upon
electrophysiological studies, the latter has been designated
as the volume-sensitive organic osmolyte anion channel
(VSOAC) and mediates the rapid efflux of triethylamines and
amino acids, in addition to inositol (Jackson and Strange
1993; Goldstein and Davis 1994; Ruhfus and Kinne 1996;
Jackson and Madsen 1997). VSOAC-mediated inositol efflux
is dependent upon the non-hydrolytic binding of ATP and
can be regulated by Gai, protein kinases A and C, tyrosine
kinases and lipoxygenases (Strange et al. 1993; Ruhfus et al.
1996; Karihaloo et al. 1997; Song et al. 1998; Novak et al.
2000). VSOAC, the molecular characteristics of which have
yet to be identified, is characterized on the basis of its
inhibition by Cl– channel blockers such as niflumic acid and
4,4¢-diisothiocyanatostilbene-2,2¢,disulfonic acid, as well as a
number of cis-unsaturated fatty acids (Strange et al. 1993;
González et al. 1995; Ruhfus and Kinne 1996; Isaacks et al.
1999a).
Putative roles for inositol in neuropathological
conditions
A number of conditions have been identified in which
alteration in inositol disposition may play a role, for example
either as a physiologically important osmolyte or as a
precursor molecule for phosphoinositide synthesis.
Disorders of volume regulation in the nervous system
In functioning neural and non-neural cells, electrolytes are
transported across the plasma membrane, and the composi-
tion of osmotically active particles inside the cell is in a
constant state of flux. Unless the osmolyte concentration is
tightly regulated, bulk flow of water across the plasma
membrane may result in damaging changes in cell volume.
To maintain cell volume, acute changes in tonicity are
regulated by changes in the transport of Na+, K+, H+ or Cl–
across the plasma membrane, whereas chronic changes in
tonicity are offset by the transport of ‘compatible’ or ‘non-
perturbing’ organic osmolytes, primarily inositol (Strange
1992; Lang et al. 1998).
At least part of the pathogenesis of Down’s syndrome may
be related to the function of inositol as an osmolyte in the
nervous system. Band q22 of human chromosome 21, which
contains the gene encoding SMIT, is triplicated (Berry et al.
1995), and the inositol concentrations in the brain and CSF
are 30–50% higher than in controls (Shetty et al. 1995b;
Shonk and Ross 1995; Berry et al. 1999; Huang et al. 1999).
Fetal CSF, which has a 10-fold higher concentration of
inositol than that of the adult mammal (Battaglia et al. 1961),
is even further enriched in Down’s syndrome, and the excess
of the polyol has been linked to osmolyte and electrolyte
imbalances in the developing CNS. Inositol concentrations
are also elevated in Ts65Dn mice, which possess three copies
of mouse chromosome 16 – homologous to human chromo-
some 21 (Shetty et al. 2000). The triplication of SMIT
results in the predicted 50% increase in inositol uptake in the
trisomic fetal cortical neurons (Acevedo et al. 1997).
Under conditions of extended hypernatremia, the brain
accumulates inositol to offset water loss (Lohr et al. 1988;
Lien et al. 1990; Lee et al. 1994). If the hypernatremia is
corrected too rapidly, the sudden osmotic gradient produces
cerebral edema, which may cause seizures or even death as
the swelling brain is driven against the unyielding skull
(Gullans and Verbalis 1993; Jackson and Madsen 1997).
Accordingly, protracted hyponatremia results in a depletion
of brain inositol reserves, and the administration of isotonic
fluids can produce cerebral dehydration, shrinkage and
myelinolysis (Thurston et al. 1989; Videen et al. 1995).
Inositol transport is also altered in stroke, a condition in
which neurons around a focal ischemic zone become hypoxic,
with a concomitant loss of ATP. The latter results in a rise in
intracellular electrolyte concentrations and in an increase in
intracellular osmolyte loads caused by the accumulation of
catabolites (Venkatachalam and Buja 1994). Both of these
events contribute to cytotoxic edema, which would ordinarily
be countered by inositol efflux (Nonaka et al. 1998). How-
ever, because VSOAC activity requires ATP, efflux is
diminished, thereby exacerbating neuronal swelling (Jackson
et al. 1994). Physical trauma to the brain can compromise the
blood–brain barrier, with a concomitant leakage of ions and
macromolecules into the cerebral extracellular space, which in
turn results in vasogenic edema and the triggering of an
up-regulation of SMIT mRNA and cellular inositol uptake
(Yamashita et al. 1997).
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Alterations in inositol transport are also implicated in
hepatic encephalopathy. This condition is associated with
hyperammonemia, which results in astrocyte swelling and a
loss of cerebral inositol (Haussinger 1994). In cultured
astrocytes incubated with NH4
+, there is a marked reduction
in inositol uptake, which reflects both a reduction in the
number of transporter molecules and their affinity for
inositol. Ammonia also increases the fast efflux of inositol
from these astrocytes (Isaacks et al. 1999b). Both the
reduction in inositol influx and the accelerated efflux of
inositol may represent adaptive changes to counteract the
ammonia-induced swelling of astrocytes.
Bipolar disorder: Li+ and the inositol depletion hypothesis
The discovery that lithium selectively blocks the action of
IMPase (Hallcher and Sherman 1980) was successfully
exploited by Berridge and colleagues in concert with the use
of [3H]inositol to demonstrate ligand-stimulated activation of
the phosphoinositide-mediated second messenger system in
intact cells (Berridge et al. 1982). They further hypothesized
that the well-known psychotherapeutic action of Li+ in mania
could be attributed to its block of IMPase (Berridge et al.
1989), with a concomitant reduction in the synthesis of
phosphoinositides. Li+ administered in vivo leads to an
accumulation of inositol monophosphate (Allison et al.
1976). When brain slices are incubated in the presence of
Li+, receptor activation results in a substantial increase in the
formation of inositol mono- and bisphosphates, whereas
conversely, the production of inositol tris- and tetrakisphos-
phates is reduced (Batty and Nahorski 1985; Kennedy et al.
1989, 1990; but see also Lee et al. 1992). The depletion
hypothesis proposes that Li+ also decreases free inositol that
is required as cosubstrate with cytidine diphosphodiacyl-
glycerol (CDP-DAG, see Fig. 2) for PI formation via PI
synthase. Depletion of the inositol in the presence of Li+
could then slow the metabolic sequence; whereby PIP2, the
precursor of the messenger molecules I(1,4,5)P3 and DAG, is
regenerated. In keeping with this possibility, a reduction in
PIP2 supply has been observed in a non-neural cell line
(CHO) transfected with the cDNA for the M1 muscarinic
receptor (CHO-M1) following chronic receptor activation in
the presence of Li+ (Jenkinson et al. 1994). An appealing
aspect of the inositol depletion hypothesis is the uncompet-
itive nature of the Li+ block of IMPase: the inhibition is
enhanced by its substrate, inositol monophosphate. Thus, in
‘hyperactive’ cells, with rapid phosphoinositide recycling
and a concomitantly larger production of inositol monophos-
phates [I(1)P, I(3)P and I(4)P], greater inhibition by Li+ is
proposed to occur, with a lesser block in ‘normal’¢ cells.
However, in experimental animals administered Li+ at doses
equivalent to human therapeutic levels, there is only a small
decrease in brain inositol concentration (Allison and Stewart
1971), which remains above the established Km for PI
synthase (Benjamins and Agranoff 1969; Ghalayini and
Eichberg 1985; Imai and Gershengorn 1987). In contrast, the
Li+ block leads to a 20-fold increase in total brain inositol
phosphates, and it has been proposed that it is this increase
that mediates the therapeutic action of Li+, rather than
inositol depletion (Agranoff and Fisher 2001). Some neuro-
nal populations may contain as much as 10–20 mM inositol,
a finding that would seem to further lower the probability that
inositol levels in such neurons can be lowered sufficiently in
the presence of Li+ to slow the phosphoinositide cycle. This
objection would be overcome if the inositol recycled in the
phosphoinositide cycle were in an intracellular pool that
excluded the bulk of brain inositol. Alternatively, Li+ may
target populations of neurons in which inositol concentra-
tions are constitutively low. Experimental demonstration of
Li+-mediated accumulation of CDP-DAG, cosubstrate with
inositol in the PI synthase reaction, would indicate depletion
of the inositol substrate. However, for CDP-DAG to
accumulate experimentally, prior depletion of cellular inos-
itol is required, as occurs in the preparation of brain slices
(Godfrey 1989; Heacock et al. 1993). In the case of cultured
cells, the ability of Li+ to augment receptor-mediated
increases in CDP-DAG accumulation is cell-specific. Thus,
whereas Li+ strongly potentiates CDP-DAG accumulation in
both cerebellar granule cells and CHO-M3 cells following
carbachol addition, no such increase is observed for SH-
SY5Y cells – a result attributed to the high concentration of
inositol in this neuroblastoma cell line (Gray et al. 1994). A
number of studies have reported a reversal of a biological
action of Li+ by inositol. For example, inositol is reported to
reverse teratogenic actions of Li+ in developing Xenopus
embryos (Busa and Gimlich 1989). In this case, further
investigations revealed the inhibition of glycogen synthase
kinase by Li+, and evidence was presented to indicate that
this metabolic site, rather than IMPase, accounts for the
deleterious effect that Li+ has on development (Klein and
Melton 1996).
Involvement of inositol in other neurological disorders
A role for inositol, either direct or indirect, has been
proposed for a number of other disorders of the CNS. For
example, intraperitoneal administration of inositol to curly
tail mice, a genetic model of folate-unrelated neural tube
defects, significantly reduced the incidence of spina bifida in
fetuses (Greene and Copp 1997). The beneficial effects of
inositol were mimicked by the administration of activators of
protein kinase C and could be prevented by Li+. It is
suggested that inositol administration results in a stimulation
of phosphoinositide turnover, which in turn up-regulates the
b-retinoic acid receptor, a gene that is expressed at reduced
levels and linked to neural tube defects. Administration of
inositol can also ameliorate the symptoms associated with
experimental diabetic peripheral neuropathy. The human
condition is associated with decreased Na+-K+-ATPase
activity and slowing of nerve conduction velocity, both of
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which are reversed in fucose-fed rats upon dietary supple-
mentation with inositol (Yorek et al. 1993). The inhibition of
inositol uptake in peripheral nerves has been implicated in
the etiology of the disease. The proposed pathway involves
hyperglycemia-induced activation of aldose reductase, lead-
ing to sorbitol accumulation and subsequent inhibition of
inositol uptake, which results in a lowered cellular inositol
concentration (Gillon and Hawthorne 1983). Inositol uptake
is also reduced in fibroblast cell lines obtained from patients
with ataxia telangiectasia, an autosomal recessive disorder
characterized, among other symptoms, by a progressive
degeneration of the cerebellum (Yorek et al. 1999). Finally,
although inositol concentrations are unaltered in Alzheimer’s
disease (Stokes and Hawthorne 1987), it has recently been
shown that myo-inositol can form a stable complex with
Ab42, a soluble form of amyloid present in plaques. Epi- and
scyllo-inositols (but not D-chiro-inositol) were also capable
of forming complexes. The interaction of inositol with Ab42
results in a complex that is non-toxic to both PC-12 cells and
primary human neurons (McLaurin et al. 2000).
Use of inositol in the treatment of human
neuropsychiatric disorders
Barkai et al. (1978) reported that significantly lower con-
centrations of inositol were present in the CSF of both
unipolar and bipolar depressed patients than were in healthy
control subjects. Some 15 years later, it was demonstrated
that oral administration of high doses of inositol (6 g/day)
could increase the concentration of inositol in the CSF by as
much as 70% (Levine et al. 1993). This observation
prompted investigations into the use of inositol in treatment
of depression. Oral administration of 12 g/day of inositol
reportedly resulted in a significant improvement in depres-
sion, as ranked by the Hamilton Depression Rating Scale,
whereas the discontinuation of treatment with inositol led to
a rapid relapse in a significant number of patients (Levine
et al. 1995; Levine 1997). Inositol administration is also
claimed to be effective in the treatment of both panic disorder
(Benjamin et al. 1995) and obsessive compulsive disorder
(Fux et al. 1996). The reported beneficial effects of inositol
became evident only after 4–6 weeks of treatment, a time
frame similar to that required for most therapeutic agents,
including Li+. Although there is clear NMR evidence that
oral administration of inositol is reported to result in a 20%
transient increase in inositol concentrations within the brain
(Moore et al. 1999), the mechanism underlying a possible
therapeutic improvement remains obscure. An unexplored
possibility is that the increased production of glucuronic acid
that accompanies a large intake of inositol increases the
excretion of P 450-hydroxylated xenotoxic or autotoxic
metabolites as their glucuronides.
Inositol administration is reported to be either ineffective
or even contraindicated in conditions such as attention deficit
hyperactivity disorder (Levine 1997), schizophrenia (Levine
et al. 1993), Alzheimer’s disease (Barak et al. 1996) and
autism (Levine et al. 1997).
Inositol hexakisphosphate
Inositol hexakisphosphate (IP6 or ‘phytic acid’) was origin-
ally identified some 80 years ago as the principal phosphate
storage molecule in plants (1–3% by weight of whole grains
and cereals). Subsequently, it has been determined that IP6 is
ubiquitously distributed in animal cells, and is one of the
most abundant of the inositol phosphates. Separation and
quantitation of highly phosphorylated inositol phosphates
from biological samples were initially problematical because
high salt concentrations are required for elution from ion-
exchange HPLC columns, which complicates the detection
and analysis. Many of these problems can be circumvented
by the use of the metal dye detection method (Mayr 1990).
High voltage electrophoresis separation at low pH (Seiffert
and Agranoff 1965) separates IP6 and IP5 isomers from one
another in a few minutes and has proven useful in biological
and soil samples (Cosgrove 1980). 31P NMR analysis has
been employed in the identification of higher inositol
phosphates (Scholz et al. 1990), and 31P/1H two-dimensional
NMR has also been applied successfully to the analysis of
phytate hydrolysates (Johnson and Barrientos 1995). Con-
centrations of IP6 in distinct brain regions range from 10 to
15 lM (Yang et al. 2001). Intracellular concentrations of IP6
are estimated to be in the range of 10–100 lM for animal
cells, whereas in the slime mold Dictyostelium, it can be 10
times higher (Shears 2001). Intracellular availability of
phytate is limited by the insolubility of its Ca2+/Mg2+ salts
and its avid electrostatic binding to protein. Apart from some
indications that the concentrations of IP6 can change during
the cell cycle, there are few documented examples of
situations in which the concentration of IP6 changes signifi-
cantly following cell stimulation. This had led to the
suggestion that the metabolic turnover of the IP6 is sluggish
– certainly quite distinct from that observed for other inositol
phosphates, such as I(1,4,5)P3. However, this impression
may be misleading as more than one metabolic pool of IP6
may be present in cells. Moreover, as discussed below, there
is strong evidence for the rapid phosphorylation of IP6 into
the diphosphoinositol polyphosphates ‘IP7’ and ‘IP8’, and
these products in turn can be dephosphorylated back to IP6
(see Fig. 3). Thus a portion of the intracellular IP6 may
represent an intermediate, rather than an end point, in the
metabolism of inositol phosphates.
The way in which IP6 is synthesized in mammalian cells is
not yet established with certainty. Unlike the situation that
exists in plants and Dictyostelium, in which IP6 can be
synthesized from inositol (via D-inositol 3-phosphate) fol-
lowing a series of positionally selective, sequential kinase
reactions (see Irvine and Schell 2001), there is no evidence
for the existence of this pathway in mammalian cells. In the
latter, it appears more likely that the synthesis of IP6 proceeds
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via the action of a newly discovered inositol polyphosphate
multikinase (mIPMK; Saiardi et al. 2001a), which can
sequentially phosphorylate I(1,4,5)P3 in both the 3¢ and 6¢
positions to yield I(1,3,4,5)P4 and then to yield I(1,3,4,5,6)P5
(see Fig. 3). Alternatively, I(1,3,4,5)P4 can be synthesized
via the action of an I(1,4,5)P3 3-kinase, a highly specific
enzyme that is enriched in neural tissues and is likely to have
evolved from mIPMK (Irvine and Schell 2001). Direct
evidence for the presence of an IP5 2-kinase (the enzyme that
would complete the synthesis of IP6) in mammalian cells is
currently lacking, although such an enzyme has been
documented in yeast (Ives et al. 2000).
A diverse array of putative physiological functions has
been assigned to IP6. For example, in non-neural tissues, IP6
has been suggested to be anti-neoplastic (Jariwalla 1999), to
prevent kidney stone formation (Grases et al. 1998) and to
act as a cellular antioxidant (Graf et al. 1987). In plants, IP6
was found to regulate stomatal pore closing (Lemtiri-Chlieh
et al. 2000). Interest in the role that IP6 may play in the CNS
stems from the fact that a large number of high-affinity IP6
binding sites can be detected in membrane preparations from
distinct brain regions (Sasakawa et al. 1995). Autoradio-
graphic studies have indicated that the distribution of these
IP6 binding sites is consistent with their localization to
neuronal cell bodies. IP6 has also been shown to bind with
even higher affinity to a number of purified proteins, several
of which are closely associated with membrane trafficking
events. These include the vesicle adaptor proteins AP-2
(Voglmaier et al. 1992) and AP-180 (Ye et al. 1995),
arrestins (Gaidarov et al. 1999) and synaptotagmin (Fukuda
et al. 1994). As a consequence, roles for IP6 in receptor
regulation (Sasakawa et al. 1995), vesicle trafficking
(Gaidarov et al. 1996) and neurotransmitter release
(Llinas et al. 1994; Ohara-Imaizumi et al. 1997) have been
proposed. In addition, IP6 has been shown to bind with high
affinity to myelin proteolipid protein and L-type Ca2+
channels. It has also been proposed to regulate PKC and
protein phosphatases (see Shears 2001 and references
therein). However, because IP6 is so highly negatively
charged, it has a propensity to bind non-specifically, and thus
the assignment of physiological functions to IP6 must be
made with caution. In this regard, Shears (2001) has
proposed a series of criteria that would distinguish IP6-
specific from IP6-non-specific actions, including the ability
of IP6 to elicit the response in the presence of physiologically
relevant concentrations of Ca2+ and/or Mg2+, the inability of
Ca2+ chelators to mimic the effect of IP6, demonstration that
other inositol phosphates, especially the diphosphoinositol
polyphosphates, are either inactive or exhibit a lower potency
and a lesser ability of inositol hexakissulfate or other
conformers of IP6 (e.g. neo- and scyllo-inositol hexaphos-
phates) to mimic the action of IP6. When these criteria are
rigorously applied, the purported ability of IP6 to regulate a
number of physiological events becomes less certain. For
example, several of the assays in which high-affinity IP6
binding to proteins has been demonstrated, e.g. to myelin
proteolipid protein (Yamaguchi et al. 1996), were conducted
in Ca2+-free media. Furthermore, in several instances, the
diphosphoinositol polyphosphates appeared to bind more
avidly than IP6 to a proposed target protein, e.g. AP-180 (Ye
et al. 1995). Calcium chelators have also, on occasion, been
found to mimic the effect of IP6, e.g. as in a proposed
extracellular neuromodulatory role for IP6 (Vallejo et al.
1987; Sun et al. 1992). Nonetheless, an IP6-dependent
protein kinase that phosphorylates pacsin/syndapin I, a
protein involved in synaptic vesicle recycling, has recently
I(1,3,4,5)P4
I(1,4,5)P3


































5,6(PP)2 - I(1,3,4)P3 ?
Fig. 3 Biosynthesis and degradation of higher inositol phosphates.
Large numerals below vertical bars correspond to the number of
phosphate molecules in each inositol phosphate depicted. Small col-
ored numerals refer to enzymes as follows. Phosphotransfereases
(kinases and synthases) are in green and phosphatases are in mauve.
1, inositol-(1,4,5)P3-3-kinase; 2, inositol-(1,3,4,5)P4-3-phosphatase
[The I(1,3,4,5)P4-3¢-phosphatase activity in brain (Höer et al. 1990) is
secondary to 5¢-phosphatase action, yielding I(1,3,4)P3, which can
re-enter the synthetic pathway following conversion via kinases (not
shown) to IP5. Loss of the 3-phosphate activity is also catalyzed by
PTEN (Maehama and Dixon 1998).]; 3, inositol polyphosphate multi-
kinase; 4, inositol-(1,4,5,6)P4-3-kinase; 5, inositol-(1,3,4,5,6)-2-kinase
(the presence of this enzyme in brain has not yet been confirmed); 6,
diphosphoinositol polyphosphate synthase (‘IP6 kinase’); 7, bisdi-
phosphoinositol polyphosphate synthase (‘IP7 kinase’); 8, multiple
inositol polyphosphate phosphatase.
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been identified that on the whole satisfies most of the stated
criteria (Hilton et al. 2001).
Two putative roles of IP6 linked to nuclear function have
emerged recently. IP6 is reported to activate a repair
mechanism for radiation- and chemically induced double-
stranded breaks in DNA via activation of a DNA-dependent
protein kinase (Hanakahi et al. 2000). The latter, which is
part of a multimeric DNA end-joining complex, possesses a
putative binding domain for IP6. Other inositol phosphates,
as well as inositol hexakissulfate, are less effective, and the
effect of IP6 can be observed at physiological Mg
2+
concentrations (Hanakahi et al. 2000). A second proposed
nuclear role for IP6, based upon mutation studies in yeast, is
the regulation of nuclear mRNA transport. York et al. (1999)
have identified four yeast genes involved in mRNA export,
three of which encode for enzymes involved, either proxi-
mally or distally, in IP6 synthesis. Deletion of IP6 kinase (see
below) does not impair mRNA export, thereby eliminating
the involvement of the diphosphoinositol polyphosphates
(Saiardi et al. 2000). Additional support (albeit correlative)
for a link between IP6 availability and mRNA export comes
from studies with mammalian cells in which transfection
with the SopB protein (a Salmonella virulence protein, which
can act as an inositol phosphatase) results in a reduction of
both parameters (Feng et al. 2001), although results obtained
with SopB need to be interpreted with caution because of the
multiple effects of SopB on cellular processes (see Shears
2001). These results, taken collectively, nonetheless raise the
intriguing prospect that IP6 plays a key role in nuclear
function.
Diphosphoinositol polyphosphates
Much of our present knowledge regarding the metabolism of
these inositol polyphosphates is derived from studies with
3H- or 32P-labeled substrates and cloned recombinant
enzymes. Although there existed previous evidence from
anion-exchange chromatography for the presence of inositol-
containing compounds that were more polar than IP6
(Europe-Finner et al. 1991), the first clear-cut identification
of inositol phosphates containing energy-rich pyrophospho-
ryl residues was obtained in 1993 from two independent
laboratories. Investigations with cell-free lysates obtained
from Dictyostelium or AR4–2J pancreatoma cells that had
been incubated with radiolabeled IP6 (Menniti et al. 1993;
Stephens et al. 1993) or, alternatively, intact hepatocytes
incubated with [3H]inositol (Glennon and Shears 1993), led
to the identification of three diphosphoinositol polyphos-
phates: diphosphoinositol tetrakisphosphate (PP-IP4), di-
phosphoinositol pentakisphosphate (PP-IP5, also known as
‘IP7’) and bisdiphosphoinositol tetrakisphosphate ([PP]2-IP4,
also known as ‘IP8’; see Fig. 3). The concentrations of the
diphosphoinositol polyphosphates are relatively low in
mammalian cells (1 lM), but are up to 300 times higher in
Dictyostelium (Stephens et al. 1993). Structural analyses
utilizing metal-dye-detection HPLC procedures reveal that in
mammalian cell lines the major isomers are likely to be 5-PP-
IP4, 5-PP-IP5 and 5,6-(PP)2-IP4 (Albert et al. 1997).
The precursor for PP-IP4 synthesis is IP(1,3,4,5,6)P5. The
latter can then be phosphorylated to PP-IP4 by the action of
mIPMK (Saiardi et al. 2001a). Alternatively, any one of the
three identified IP6-kinase isoforms derived from distinct
genes and cloned from mammals (Voglmaier et al. 1996;
Saiardi et al. 2000, 2001a) can also phosphorylate IP5 to PP-
IP4 (and PP-IP4 to (PP2)-IP3 – see Fig. 3). However, IP6 is
the preferred substrate for the enzyme. The three IP6 kinases
(K1, K2 and K3; MW ¼ 49, 49 and 46 kDa, respectively)
exhibit 45–65% similarities in amino acid sequences, and all
are highly enriched in brain (Saiardi et al. 2001a). The Km
for IP6 is approximately 1 lM, whereas the enzyme exhibits a
much lower affinity for its cosubstrate, ATP (1–2 mM). When
transiently transfected in a non-neural cell, human embryonic
kidney cell 293 (HEK293), the K2 and K3 isoforms are
preferentially localized to the nuclei and cytoplasm, respec-
tively, whereas the K1 isoform is found at both subcellular
locations. A selective kinase that preferentially phosphory-
lates PP-IP5 to (PP)2-IP4 (‘IP7’ kinase) has also been purified
from brain (Huang et al. 1998), but has not yet been cloned.
This enzyme is enriched in the cytoplasm, and has a MW of
56 kDa and exhibits a 10-fold higher affinity for PP-IP5 than
for IP6 (1 vs. 10 lM). Both IP6 and PP-IP5 kinases can act
reversibly under physiological conditions and thereby act as
ATP synthases. These observations have prompted the
suggestion that diphosphoinositol polyphosphates may act
as primary phosphate donors to acceptors other than ADP,
such as proteins (Voglmaier et al. 1996; Huang et al. 1998),
but none have as yet been identified.
Diphosphoinositol polyphosphates are very active meta-
bolically. This becomes evident when their breakdown is
prevented by the inclusion of fluoride to inhibit phosphatase
action (Menniti et al. 1993). By use of this F– ‘metabolic
trap’ technique, it has been calculated that 20–50% of the
cellular IP6 reservoir cycles through the diphosphoinositol
polyphosphates per hour. A similar flux occurs between IP5
and PP-IP4 (Menniti et al. 1993). The observation that
diphosphoinositol polyphosphates turn over rapidly has
stimulated interest in their potential physiological roles.
Most emphasis to date has been placed on the possibility that
membrane trafficking events are regulated by these pyro-
phosphorylated inositol phosphates. In yeast, deletion of the
IP6 kinase results in a disruption of vacuole biogenesis
(Saiardi et al. 2000). In mammals, PP-IP5 binds tightly
(Kd ¼ 20 nM) to AP-3 (a clathrin adaptor protein) and is a
potent inhibitor of AP-3-dependent assembly of clathrin
cages (Ye et al. 1995). Clathrin is a major protein in brain
(1% of total), and its assembly is a key event in
endocytosis. PP-IP5 also binds with high affinity to AP-2,
another adaptor protein that promotes the assembly of clathrin
cages (Shears et al. 1995). Because dephosphorylation of
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PP-IP5 to IP6 should result in a less potent inhibition of
clathrin assembly, this metabolic step could conceivably
result in the activation of endocytosis (Safrany et al. 1999).
Of possible relevance is the recent observation that PP-IP5
(like IP6) can stimulate a protein kinase that selectively
phosphorylates pacsin/syndapin I (Hilton et al. 2001), a
protein involved in synaptic vesicle recycling. In addition,
PP-IP5 binds with high affinity to coatomer, a cytosolic
multimeric complex that also controls membrane trafficking
events between the Golgi complex and endoplasmic reticu-
lum (Fleischer et al. 1994; Ali et al. 1995).
The turnover of diphosphoinositol polyphosphates may
also be regulated, at least in some instances, by agonist
occupancy of cell surface receptors. For example, in a
smooth muscle cell line, either the activation of b-adrenergic
receptors, or the addition of a cell-permeant analog of cAMP,
results in a 70% reduction of (PP)2-IP4 concentration (but not
that of either PP-IP4 or PP-IP5; see Safrany and Shears 1998).
Atypically, this is not mediated via protein kinase A
activation. A sustained depletion of intracellular Ca2+ in
hepatocytes following the addition of thapsigargin has also
been shown to reduce the steady state concentrations of
diphosphoinositol polyphosphates by 50%. However, it
seems unlikely that receptor activation of phospholipase C
regulates the turnover of the diphosphoinositol polyphos-
phates, as the addition of vasopressin to hepatocytes does not
alter the steady state concentrations of either PP-IP5 or (PP)2-
IP4 (Glennon and Shears 1993).
There are three potential enzymatic routes for the
dephosphorylation of the diphosphoinositol polyphosphates
(Fig. 3). The first is the reversal of the IP6- and PP-IP5-kinase
reactions, as outlined above. Secondly, the multiple inositol
polyphosphate phosphatase can carry out the dephosphory-
lation (Craxton et al. 1997). This enzyme, first cloned from
liver, is also enriched in brain. More recently, a group of
enzymes known as the diphosphoinositol polyphosphate
phosphatases (DIPP) have been identified. One of these is
reported to be regulated by Li+ (Hua et al. 2001). The first
member of this family to be isolated was an 18-kDa, Mg2+-
dependent enzyme that exhibited high affinity for both PP-
IP5 and (PP)2-IP4, and was present in brain along with other
tissues (Safrany et al. 1998). It was subsequently demon-
strated that PP-IP4 is also a substrate for DIPP (Caffrey et al.
2000). Two additional isoforms of DIPP (MW ¼ 21 kDa)
have been identified, DIPP2a and DIPP2b, the latter being
distinguishable by the presence of an additional glutamine
residue. This change results in an enzyme that is 65–80% less
active against PP-IP5, PP-IP4 or (PP)2-IP4 than is the
a-isoform (Caffrey et al. 2000). The purification and molec-
ular cloning of DIPPs has revealed them to contain a Nudix
(nucleoside diphosphate linked to some other moiety, X)
motif. Nudix, also known as a MutT motif, is a 23 amino
acid residue domain found in enzymes that protect cell
integrity against oxygen radicals. The DIPPs are unusual in
that they are the first example of a MutT-type enzyme that
can readily metabolize a class of substrates other than
nucleoside diphosphates. However, the diphosphoinositol
polyphosphates do not appear to be general substrates for
other MutT-type enzymes (see Safrany et al. 1999).
Conclusions
Although the first indication of the importance of inositol-
containing phospholipids in cell signaling events was
obtained nearly 50 years ago (Hokin and Hokin 1953,
1955), discovery of new roles for both the phosphoinositides
and the water-soluble inositol phosphates continue unabated.
In this review, we have focused on the importance of myo-
inositol, the basic building block, and its water-soluble
phosphates, in CNS function. Not only does inositol serve as
precursor for the synthesis of inositol phospholipids, but it
also plays an essential role in the regulation of cell volume
within the CNS. The versatility of function of inositol and its
phosphates is further illustrated by the case of IP6 and
disphosphoinositol polyphosphates, highly phosphorylated
forms of inositol that are readily synthesized in the brain and
are now linked to both the regulation of nuclear function and
to endo/exocytosis.
Inositol plays an essential role in eukaryotes, and the
presence of inositol-containing phospholipids has been
documented in some eubacteria and Archebacteria. Thus, it
is likely that inositol was one of the earliest organic
molecules to evolve, and that during the course of evolution
it has been adapted to serve in many functions. Given the
variety of possible inositol phosphates, it is likely that
additional roles for inositol and its phosphates in the nervous
system are yet to be uncovered.
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González E., Sánchez-Olea R. and Pasantes-Morales H. (1995) Inhibi-
tion by Cl– channel blockers of the volume-activated, diffusional
mechanism of inositol transport in primary astrocytes in culture.
Neurochem. Res. 20, 895–900.
Graf E., Empson K. L. and Eaton J. W. (1987) Phytic acid. A natural
antioxidant. J. Biol. Chem. 262, 11647–11650.
Grases F., Garcı́a-Gonzalez R., Torres J. J. and Llobera A. (1998) Effects
of phytic acid on renal stone formation in rats. Scand. J. Urol.
Nephrol. 32, 262–265.
Gray D. W., Challiss R. A. and Nahorski S. R. (1994) Differential effects
of lithium on muscarinic cholinoceptor-stimulated CMP-phos-
phatidate accumulation in cerebellar granule cells, CHO-M3 cells,
and SH-SY5Y neuroblastoma cells. J. Neurochem. 63, 1354–1360.
Greene N. D. and Copp A. J. (1997) Inositol prevents folate-resistant
neural tube defects in the mouse. Nat. Med. 3, 60–66.
Greene D. A. and Lattimer S. A. (1982) Sodium- and energy-dependent
uptake of myo-inositol by rabbit peripheral nerve. J. Clin. Invest.
70, 1009–1018.
Gullans S. R. and Verbalis J. G. (1993) Control of brain volume during
hyperosmolar and hypoosmolar conditions. Annu. Rev. Med. 44,
289–301.
Guo W., Shimada S., Tajiri H., Yamauchi A., Yamashita T., Okada S. and
Tohyama M. (1997) Developmental regulation of Na+/myo-inositol
cotransporter gene expression. Brain Res. Mol. Brain Res. 51, 91–
96.
Hager K., Hazama A., Kwon H. M., Loo D. D., Handler J. S. and Wright
E. M. (1995) Kinetics and specificity of the renal Na+/myo-inositol
cotransporter expressed in Xenopus oocytes. J. Membr. Biol. 143,
103–113.
Hallcher M. and Sherman W. R. (1980) The effects of lithium ion and
other agents on the activity of myo-inositol-1-phosphatase from
bovine brain. J. Biol. Chem. 255, 10896–10901.
Hanakahi L. A., Bartlet-Jones M., Chappell C., Pappin D. and West S. C.
(2000) Binding of inositol phosphate to DNA-PK and stimulation
of double-strand break repair. Cell 102, 721–729.
Hauser G. and Finelli V. N. (1963) The biosynthesis of free and phos-
phatide myo-inositol from glucose in mammalian tissues. J. Biol.
Chem. 238, 3224–3228.
Haussinger D., Laubenberger J., vom Dahl S., Ernst T., Bayer S., Langer
M., Gerok W. and Hennig J. (1994) Proton magnetic resonance
spectroscopy studies on human brain myo-inositol in hypo-osmo-
larity and hepatic encephalopathy. Gastroenterology 107, 1475–
1480.
Heacock A. M., Seguin E. B. and Agranoff B. W. (1993) Measurement
of receptor-activated phosphoinositide turnover in rat brain: non-
equivalence of inositol phosphate and CDP-diacylglycerol forma-
tion. J. Neurochem. 60, 1087–1092.
Hediger M. A., Coady M. J., Ikeda T. S. and Wright E. M. (1987)
Expression cloning and cDNA sequencing of the Na+/glucose
co-transporter. Nature 330, 379–381.
Hilton J. M., Plomann M., Ritter B., Modregger J., Freeman H. N., Falck
J. R., Krishna U. M. and Tobin A. B. (2001) Phosphorylation of a
synaptic vesicle-associated protein by an inositol hexakisphos-
phate-regulated protein kinase. J. Biol. Chem. 276, 16341–16347.
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Häussinger D. (1998) Functional significance of cell Volume
regulatory mechanisms. Physiol. Rev. 78, 247–306.
Lee C. H., Dixon J. F., Reichman M., Moummi C., Los G. and Hokin
L. E. (1992) Li+ increases accumulation of inositol 1,4,5-tris-
phosphate and inositol 1,3,4,5-tetrakisphosphate in cholinergically
stimulated brain cortex slices in guinea pig, mouse and rat. The
increases require inositol supplementation in mouse and rat but not
in guinea pig. Biochem. J. 282, 377–385.
Lee J. H., Arcinue E. and Ross B. D. (1994) Brief report: organic
osmolytes in the brain of an infant with hypernatremia. N. Engl. J.
Med. 331, 439–442.
Lemtiri-Chlieh F., MacRobbie E. A. and Brearley C. A. (2000) Inositol
hexakisphosphate is a physiological signal regulating the
K+-inward rectifying conductance in guard cells. Proc. Natl Acad.
Sci. USA 97, 8687–8692.
Levine J. (1997) Controlled trials of inositol in psychiatry. Eur. Neuro-
psychopharmacol. 7, 147–155.
Levine J., Gonzalves M., Barbam I., Stier S., Elizur A., Kofman O. and
Belmaker R. H. (1993) Inositol 6 gm daily may be effective in
depression but not in schizophrenia. Hum. Psychopharmacol. 8,
49–53.
Levine J., Barak Y., Gonzalves M., Elizur A., Schor H., Kofman O. and
Belmaker R. H. (1995) Double blind study of inositol versus
placebo in depression. Am. J. Psychiatry 152, 792–794.
Levine J., Aviram A., Holan A., Ring A., Barak Y. and Belmaker R. H.
(1997) Inositol treatment of autism. J. Neural Transm. 104, 307–
310.
Lien Y.-H. H., Shapiro J. I. and Chan L. (1990) Effects of hypernatremia
on organic brain osmoles. J. Clin. Invest. 85, 1427–1435.
Llinas R., SugimoriM., Lang E. J.,MoritaM., FukudaM., NiinobeM. and
Mikoshiba K. (1994) The inositol high-polyphosphate series blocks
synaptic transmission by preventing vesicular fusion: a squid giant
synapse study. Proc. Natl Acad. Sci. USA 91, 12990–12993.
Lohr J. W., McReynolds J., Grimaldi T. and Acara M. (1988) Effect of
acute and chronic hypernatremia on myoinositol and sorbitol
concentration in rat brain and kidney. Life Sci. 43, 271–276.
Long C. (1961) Biochemists’ Handbook p. 640. D. Van Nostrand
Company, Inc, Princeton, New Jersey.
Low M. G. (2000) Glycosylphosphatidylinositol-anchored proteins and
their phospholipases, in Biology of Phosphoinositides (Cockcroft
S., ed.), pp. 210–239. Oxford University Press, Oxford.
Lubrich B., Spleiss O., Gebicke-Haerter P. J. and van Calker D. (2000)
Differential expression, activity and regulation of the sodium/myo-
inositol cotransporter in astrocyte cultures from different regions of
the rat brain. Neuropharmacology. 39, 680–690.
MacGregor L. C. and Matschinsky F. M. (1984) An enzymatic fluori-
metric assay for myo-inositol. Anal. Biochem. 141, 382–389.
Maeda T. and Eisenberg F. Jr (1980) Purification, structure, and catalytic
properties of 1-myo-inositol-1-phosphate synthase from rat testis.
J. Biol. Chem. 255, 8458–8464.
Maehama T. and Dixon J. E. (1998) The tumor suppressor, PTEN/
MMAC1, dephosphorylates the lipid second messenger, phos-
phatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273, 13375–
13378.
Martin J. B., Laussmann T., Bakker-Grunwald T., Vogel G. and Klein G.
(2000) neo-Inositol polyphosphates in the amoeba Entamoeba
histolytica. J. Biol. Chem. 275, 10134–10140.
Matskevitch J., Wagner C. A., Risler T., Kwon H. M., Handler J. S.,
Waldegger S., Busch A. E. and Lang F. (1998) Effect of
Inositol and inositol polyphosphates in CNS 751
 2002 International Society for Neurochemistry, Journal of Neurochemistry, 82, 736–754
extracellular pH on the myo-inositol transporter SMIT expressed in
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